Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

New Objective and McKinley Scientific Announce a Strategic Co-Marketing Collaboration

Published: Friday, November 30, 2012
Last Updated: Thursday, November 29, 2012
Bookmark and Share
Co-marketing agreement designed to enable and expand key applications for delivery of high-performance LC-MS systems.

McKinley Scientific, LLC and New Objective, Inc. have announced that they have entered into a strategic co-marketing and development agreement designed to enable and expand key applications for delivery of high-performance LC-MS systems.

This includes the financing and support services for mass spectrometry provided by McKinley Scientific and New Objective's industry-recognized nanospray front-end technologies.

Together, the firms intend to co-market their products through industry publications and trade shows, and the development of distribution and services to deliver high-end MS solutions.

Paul Corcoran, President and CEO of McKinley Scientific commented that: "New Objective and McKinley Scientific have enjoyed a close relationship for many years. It was a natural progression for us to combine our collective strengths into a mutually beneficial relationship. Our combined customer focus will yield broader and more powerful solutions with expanded choices, adaptability, and education opportunities. We are very excited to support Dr. Valaskovic along with the wonderful products and people at New Objective."

Dr. Gary Valaskovic, the co-founder and President of New Objective adds: "I am very pleased to have strengthened and formalized the excellent, long standing relationship between New Objective and McKinley Scientific. Paul Corcoran and McKinley are an outstanding team of individuals dedicated to transforming the business of mass spectrometry and related technologies in the life science marketplace. The combination of New Objective¹s world class front-end hardware and consumables, with the outstanding finance, sales, and support structure of McKinley Scientific is a winning combination for the customer, one that will enable the development of new markets for both organizations."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos